1.Maynard A. Is it worthwhile reducing hospital infection rates? In Williams JD and Taylor EW, eds. Infection in Surgical Practice. Oxford, England: Oxford University Press; 1992:119–122.
2.Graves N. Economics and preventing hospital-acquired infection. Emerg Infect Dis 2004;10:561–566.
3.Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275–283.
4.Plowman RP, Graves N, Roberts JA. Hospital Acquired Infection. London: Office of Health Economics; 1997.
5.Drummond MF, Davies LF. Evaluation of the costs and benefits of reducing hospital infection. J Hosp Infect 1991;18 (Suppl 18):85–93.
6.Cohen DR. Economic issues in infection control. J Hosp Infect 1984;5 (Supplement A):17–25.
7.Haley RW. Cost-Benefit analysis of infection control activities. In Brachman P and Bennett J, eds. Hospital Infections. Philadelphia: Lippincott-Raven; 1998:249–267.
8.Plowman RP, Graves N, Griffin MAS, et al. The rate and cost of hospital-acquired infections occurring in patients admitted to selected specialties of a district general hospital in England and the national burden imposed. J Hosp Infect 2001;47:198–209.
9.Plowman R, Graves N, Griffin M, et al. The Socio-Economie Burden of Hospital Acquired Infection. London:Public Health Laboratory Service; 2000.
10.Schulpher M. The role and estimation of productivity costs in economic valuation. In: Drummond M, McGuire A, eds. Economic Evaluation in Health Care, Merging Theory With Practice. Oxford, England: Oxford University Press; 2000:94–112.
11.Robinson R. Cost-utility analysis. BMJ 1993;307:859–62.
12.Williams ASO. Economics of coronary artery bypass grafting. BMJ 1985;291:326–9.
13.Torrance GW. Measurement of health state utilities for economic appraisal: a review. J Health Econ 1986;5:1–30.
14.Brazier J, Deverill M, Green C, Harper R, Booth A. A review of the use of health status measures in economic evaluation. Health Technol Assess 1999;3:1–164.
15.Cookson R. Willingness to pay methods in health care: a sceptical view. Health Econ 2003;12:891–894.
16.Saint S, Chenoweth C, Fendrick M. The role of economic evaluation in infection control. Am J Infect Control 2001;29:338–344.
17.Gold MR, Siegel JE, Russell LN, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
18.Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. Oxford, England: Oxford University Press; 1997.
19.Drummond MF, McGuire A. Economic Evaluation in Health Care: Merging Theory With Practice. Oxford, England: Oxford University Press; 2001.
20.Perencevich EN, Sands KE, Cosgrove SE, Guadagnoli E, Meara E, Platt R. Health and economic impact of surgical site infections diagnosed after hospital discharge. Emerg Infect Dis 2003;9:196–203.
21.Briggs AH. Handling uncertainty in economic evaluation and presenting the Results. In: Drummond M, McGuire A, eds. Economic Evaluation in Health Care, Merging Theory With Practice. Oxford, England: Oxford University Press; 2001:172–241.
22.Donaldson C, Currie G, Mitton C. Cost effectiveness analysis in health care: contraindications. BMJ 2002;325:891–894.
23.Evans C, Tavakoli M, Crawford B. Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal. Health Care Manag Sri 2004;7:43–49.
24.Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997;16:1–31.
25.Barry HC, Ebell MH, Hickner J. Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies. J Farn Pract 1997;44:49–60.
26.Jacobson JJ, Schweitzer SO, Kowalski CJ. Chemoprophylaxis of prosthetic joint patients during dental treatment: a decision-utility analysis. Oral Surg 1991;72:167–77.
27.Tsevat J, Durand-Zaleski I, Pauker SG. Cost-effectiveness of antibiotic prophylaxis for dental procedures in patients with artificial joints. Am J Public Health 1989;79:739–43.
28.Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999;18:341–364.
29.Cooper NJ, Sutton AJ, Abrams KR, Turner D, Wailoo A. Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach. Health Econ 2004;13:203–226.
30.Fenwick E. Cost-effectiveness acceptability curves—facts, fallacies and frequently asked questions. Health Econ 2004;13:405–415.
31.Cooper BS, Medley GF, Scott GM. Preliminary analysis of the transmission dynamics of nosocomial infections: stochastic and management effects. J Hosp Infect 1999;43:131–47.
32.Cooper BS, Lipsitch M. The analysis of hospital infection data using hidden Markov models. Biostatistics 2004;5:223–37.
33.Cooper BS, Medley GF, Stone SP, et al. Methicillin-resistant Staphylococcus aureus in hospitals and the community: stealth dynamics and control catastrophes. Proc Natl Acad Sci USA 2004;101:10223–8.
34.Stone WP, Larson E, Kawar LN. A systematic audit of economic evidence linking nosocomial infections and infection control interventions: 1990-2000. Am J Infect Control 2002;30:145–52.
35.Everett WD, Kipp H. Epidemiologic observations of operating room infections resulting from variations in ventilation and temperature. Am J Infect Control 1991;19:277–82.
36.Chaudhuri AK. Infection control in hospitals: has its quality-enhancing and cost-effective role been appreciated? J Hosp Infect 1993;25:1–6.
37.Fleming CA, Balaguera HU, Craven DE. Risk factors for nosocomial pneumonia: focus on prophylaxis. Med Clin North Am 2001;85:1545–63.
38.Mehtar S. The continuing problem of ‘hospital staphylococci’: why? J Chemother 1994;6(Suppl 4):25–31.